宜宾切眉好还是割双眼皮好宜宾自体软骨隆鼻价格,宜宾做假体隆鼻要多少钱,宜宾去眼袋去哪家较好,宜宾哪里冰点脱毛好,宜宾玻尿酸隆下巴方法,宜宾割双眼皮哪里最好的医院,宜宾整容医院哪家隆鼻好

The Scottish Parliament voted on Tuesday to unanimously approve a bill that would provide free feminine hygiene products to the public. The bill says products that are disposable, such as tampons and wipes, will be available to the public for free.The legislation, titled SP Bill 45A, spells out that local authorities ensure “period products” be obtainable free of charge to all persons who need them; education providers make period products obtainable for free for students; and that period products be available for free in public buildings.The legislation points out that Scotland is the first nation in the world to implement such a law, so it is unknown what the cost might be to the government.The Scottish government estimates there are nearly 1.6 million women of menstruation age in Scotland.“Thank you to everyone who has campaigned for period dignity and to my MSP colleagues for backing the Bill tonight. A proud day for Scotland and a signal to the world that free universal access to period products can be achieved,” the bill’s sponsor Monica Lennon tweeted."Proud to vote for this groundbreaking legislation, making Scotland the first country in the world to provide free period products for all who need them. An important policy for women and girls," Scotland's First Minister Nicola Sturgeon said on Twitter. 1337

The Rev. Billy Graham's body will lie in honor in the U.S. Capitol for two days next week.U.S. House Speaker Paul Ryan said the public and members of Congress will be invited to pay respects to "America's Pastor" on Feb. 28 and March 1. The last time a private citizen laid in honor at the Capitol was 2005, when Rosa Parks died.Graham, a famous evangelist who preached to hundreds of millions of people in 185 countries around the world, died Wednesday, Feb. 21. He was 99 years old.On Monday and Tuesday his body will lie in repose at his library in Charlotte, North Carolina, according to the Associated Press. A funeral is scheduled for March 2 on the grounds of the library. 687

The Trump campaign has officially requested a recount in two Wisconsin counties, just one day after all 72 counties had reported they finished their canvassing.President Donald Trump and his campaign had a deadline of 5 p.m. Wednesday to demand a recount in the state.The Wisconsin Election Commission (WEC) said the request could be delivered to the commission in person or filed electronically, as long as it was received by 5 p.m.On Wednesday, the Trump campaign ordered a recount in both Milwaukee and Dane Counties — two of the most populous and Democratic-leaning counties in the state.The WEC added that the campaign wired million Tuesday evening.The fees for a recount vary based on where the president would like a recount. The whole state is much more expensive than a county by county recount.The news of the recount comes after The Associated Press projected Joe Biden as the winner in Wisconsin. Biden leads Trump statewide by about 0.3%, or 20,000 votes.This story was originally published by Julia Marshall on WTMJ in Milwaukee, Wisconsin. 1065

The terror attack on New York City's West-Side bike path has President Trump calling for congress to eliminate the "Diversity Visa" program.Congress created it in 1990. It was signed into law by President George W. Bush.Among the San Diegans who are here because of the visa program is Anna Riazanova.In 1993, Riazanova, a native of Russia, entered the U.S. on a student visa and began studying to become a paralegal."I fell in love with the country, the people," said Riazanova.A year later, she applied for the Diversity Visa Lottery program, aimed at diversifying immigration by randomly selecting 50,000 green card applicants every year from countries with historically low U.S. immigration rates. 709

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274